Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Xiaflex (collagenase clostridium histolyticum)
BLA #125338
REMS last update: 01/25/2017



What is the purpose of the REMS?

    1. The goal of the XIAFLEX REMS is to mitigate the risks of corporal rupture (penile fracture) and other serious penile injuries associated with the use of XIAFLEX for Peyronie’s disease by:
      1. Training healthcare providers in how to properly administer XIAFLEX.
      2. Informing healthcare providers about the risks of corporal rupture (penile fracture)and other serious injuries to the penis.
      3. Informing healthcare providers about the need to counsel patients to communicate that risks of corporal rupture and other serious penile injuries are associated with the use of XIAFLEX in treating Peyronie’s disease and that patient adherence to post-injection instructions is important for the drug’s safety and effectiveness.
      4. Ensuring that XIAFLEX is dispensed only in certified pharmacies or healthcare settings for the treatment of Peyronie’s disease.
      5. Informing patients about the risks of corporal rupture and other serious penile injuries associated with the use of XIAFLEX in treating Peyronie’s disease and that adherence to post-injection instructions is important for the drug’s safety and effectiveness.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

Healthcare Providers who prescribe Xiaflex

To be able to prescribe Xiaflex
Before writing the first prescription for a patient

Healthcare settings and pharmacies that dispense Xiaflex

To be able to dispense Xiaflex
  • Designate an authorized representative to carry out the certification process on behalf of the healthcare setting.
  • Establish processes and procedures to verify that prescribers are certified.
  • Enroll in the REMS by completing and submitting the Pharmacy/Healthcare Setting Enrollment Form for Peyronie’s disease.
    | Pharmacy/Healthcare Setting Enrollment Form for Peyronie’s disease |
Before dispensing Xiaflex
  • Verify that the prescriber is certified.
Ongoing
  • Do not distribute, transfer, loan, or sell product.
  • Maintain records of current certified prescribers.
  • Cooperate with audits carried out by the sponsor to ensure that all processes and procedures are in place and are being followed.

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Xiaflex REMS, see the DailyMed link(s).
Material Name Material Name Link
Healthcare Provider Enrollment Form for Peyronie’s disease (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_HCP_Enrollment_Form.pdf
Patient Counseling Tool, What You Need to Know About XIAFLEX Treatment for Peyronie’s disease: A Patient Guide (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_Patient_Counseling_Tool.pdf
Pharmacy/Healthcare Setting Enrollment Form for Peyronie’s disease (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_Pharmacy_Enrollment_Form .pdf
REMS document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_REMS_document.pdf
REMS full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_REMS_full.pdf
REMS Training Guide for Administering XIAFLEX for Peyronie’s disease (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_Training_Guide.pdf
REMS Training Video for Administering XIAFLEX for Peyronie’s disease (accessed at www.XIAFLEXREMS.com) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_video_transcript.pdf
REMS website screenshot (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Xiaflex_2017-01-25_website_screenshot.pdf

What updates have been made to the REMS?

Date Summary of change
01/25/2017 Revised to correct a typographical error (s).
11/28/2016

  1. Modified the REMS for the treatment of Dupuytren’s contracture to:
    1. Remove the communication plan from the REMS.
    2. Release the REMS requirements.
  2. Modified the REMS for the treatment of Peyronie’s disease to:
    1. Change to the Prescriber Material, “Training Guide for the Administration of Xiaflex for Peyronie’s Disease”
    2. Change to the Patient Counseling Tool, “What You Need to Know About XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide”
    3. Align the Training Video with the Prescriber Material.
    4. Align the Xiaflex REMS Program website with the Prescriber Material.
    5. Remove information related to the communication plan.
10/20/2014

  1. Modified the REMS for the treatment of Dupuytren’s contracture to:
  1. Include the following change to information in the dosing regimen: two concurrent injections of Xiaflex into palpable cords affecting multiple joints in the same hand in adult patients with Dupuytren’s contracture with finger extension procedure 24 to 72 hours after injection; and
  2. Include the risk of skin laceration requiring skin graft in patients treated with Xiaflex (collagenase clostridium histolyticum) in the communication plan materials (Dear Healthcare Provider Letter; Training Guide for the Administration of Xiaflex; and Xiaflex Procedure Training Video).
12/06/2013 Modified to ensure that the benefits of the drug outweigh the risk of corporal fracture (penile fracture) and other serious penile injuries by ensuring that healthcare providers who prescribe XIAFLEX (collagenase clostridium histolyticum) for Peyronie’s disease are specially certified, and that pharmacies or healthcare settings that dispense XIAFLEX (collagenase clostridium histolyticum) for Peyronie’s disease are specially certified.
02/24/2012 Modified to:

  1. Eliminate the requirement for the Medication Guide as an element of the REMS.
  2. Address the requirements in our June 1, 2011 REMS Modification Notification letter to revise some of the communication plan materials to more effectively educate prescribers about the risks when injecting Xiaflex into a cord of the proximal interphalangeal joint of the fifth finger.
02/02/2010 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English